Clinicopathologic and molecular characteristics of synchronous colorectal cancers: Heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors

Diseases of the Colon and Rectum

Volumn 55, Issue 2, 2012, Pages 181-190

  Bae, Jeong M ^a   Cho, Nam Yun ^a   Kim, Tae You ^a   Kang, Gyeong H ^a  

^a Seoul National University   (South Korea)

Author keywords

CpG island methylator phenotype; Epigenetic instability; Microsatellite instability; Synchronous colorectal cancer

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DISEASE COURSE; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KOREA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PROGRESSION FREE SURVIVAL; UNIVERSITY HOSPITAL; COLORECTAL TUMOR; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; MIDDLE AGED; MORTALITY; MULTIPLE CANCER; MUTATION; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; DNA MISMATCH REPAIR; EPIGENESIS, GENETIC; FEMALE; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84857952066     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/DCR.0b013e31823c46ce     Document Type: Article

References (33)

1. Ueno M, Muto T, Oya M, et al. Multiple primary cancer: An experience at the Cancer Institute Hospital with special reference to colorectal cancer. Int J Clin Oncol. 2003;8:162-167. (Pubitemid 36897286)
2. Nikoloudis N, Saliangas K, Economou A, et al. Synchronous colorectal cancer. Tech Coloproctol. 2004;8(suppl 1):s177-s179. (Pubitemid 40394551)
3. Papadopoulos V, Michalopoulos A, Basdanis G, et al. Synchronous and metachronous colorectal carcinoma. Tech Coloproctol. 2004;8(suppl 1):s97-s100. (Pubitemid 40394526)
4. Wang HZ, Huang XF, Wang Y, Ji JF, Gu J. Clinical features, diagnosis, treatment and prognosis of multiple primary colorectal carcinoma. World J Gastroenterol. 2004;10:2136-2139. (Pubitemid 39106977)
5. Vogelstein B, Fearon ER, Kern SE, et al. Allelotype of colorectal carcinomas. Science. 1989;244:207-211. (Pubitemid 19110299)
6. Smith G, Carey FA, Beattie J, et al. Mutations in APC, Kirstenras, and p53-Alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci U S A. 2002;99:9433-9438. (Pubitemid 34764631)
7. Peinado MA, Malkhosyan S, Velazquez A, Perucho M. Isolation and characterization of allelic losses and gains in colorectal tumors by arbitrarily primed polymerase chain reaction. Proc Natl Acad Sci U S A. 1992;89:10065-10069.
8. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138:2073-2087 e2073.
9. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96:8681-8686. (Pubitemid 29354851)
10. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4:988-993.
11. Konishi K, Shen L, Jelinek J, et al. ConcordantDNAmethylation in synchronous colorectal carcinomas. Cancer Prev Res (Phila Pa). 2009;2:814-822.
12. Nosho K, Kure S, Irahara N, et al. A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology. 2009;137: 1609-1620.
13. Kim JH, Shin SH, Kwon HJ, Cho NY, Kang GH. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch. 2009;455:485-494.
14. Lee S, Cho NY, Yoo EJ, Kim JH, Kang GH. CpG island methylator phenotype in colorectal cancers: Comparison of the new and classic CpG island methylator phenotype marker panels. Arch Pathol Lab Med. 2008;132:1657-1665.
15. Abe Y, Masuda H. Genetic alterations of sporadic colorectal cancer with microsatellite instability, especially characteristics of primary multiple colorectal cancers. J Surg Oncol. 2000;74:249-256. (Pubitemid 30660813)
16. Sugai T, Habano W, Jiao YF, et al. Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: Proposal for new molecular profile of colorectal carcinomas. J Mol Diagn. 2006;8:193-201. (Pubitemid 43811242)
17. Chang SC, Lin JK, Yang SH, et al. Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Int J Cancer. 2006;118:1721-1727. (Pubitemid 43376435)
18. Yuen ST, Davies H, Chan TL, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 2002;62:6451-6455. (Pubitemid 35364105)
19. Hamilton SR, Rubio CA, Vogelstein B, et al. Carcinoma of the colon and rectum. In: Hamilton SR, Aaltonen LA eds. World Health Organization Classification of Tumours: Tumours of the Digestive System. Lyon, France: IARC Press; 2000;101-119.
20. Lee S, Cho NY, Choi M, et al. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int. 2008;58:104-113.
21. Abe Y, Masuda H, Okubo R. Microsatellite instability of each tumor in sporadic synchronous multiple colorectal cancers. Oncol Rep. 2001;8:299-304. (Pubitemid 33758082)
22. Dykes SL, Qui H, Rothenberger DA, Garcia-Aguilar J. Evidence of a preferred molecular pathway in patients with synchronous colorectal cancer. Cancer. 2003;98:48-54. (Pubitemid 36741124)
23. Brueckl WM, Limmert T, Brabletz T, et al. Mismatch repair deficiency in sporadic synchronous colorectal cancer. Anticancer Res. 2000;20:4727-4732. (Pubitemid 32127718)
24. Norrie MW, Hawkins NJ, Todd AV, et al. The role of hMLH1 methylation in the development of synchronous sporadic colorectal carcinomas. Dis Colon Rectum. 2002;45:674-680. (Pubitemid 34507244)
25. Yalcinkaya U, Ozturk E, Ozgur T, Yerci O, Yilmazlar T. P53 expression in synchronous colorectal cancer. Saudi Med J. 2008; 29:826-831.
26. Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology. 2010;138:2044-2058.
27. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999;116:1453-1456. (Pubitemid 29258894)
28. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261-268. (Pubitemid 38256271)
29. Oya M, Takahashi S, Okuyama T, Yamaguchi M, Ueda Y. Synchronous colorectal carcinoma: Clinico-pathological features and prognosis. Jpn J Clin Oncol. 2003;33:38-43. (Pubitemid 43102879)
30. Latournerie M, Jooste V, Cottet V, et al. Epidemiology and prognosis of synchronous colorectal cancers. Br J Surg. 2008;95: 1528-1533.
31. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;58:90-96.
32. Watson P, Lin KM, Rodriguez-Bigas MA, et al. Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members. Cancer. 1998;83:259-266. (Pubitemid 28317805)
33. Drescher KM, Sharma P, Lynch HT. Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch syndrome patients. Clin Dev Immunol. 2010;2010:170432.